Tim Boreham, Stockhead's small caps correspondent joins The Australian's Wealth Editor James Kirby on this week's show. They discuss how Biotech gets hit hardest of all, one reason this sector may recover first and three ASX biotech stocks for you to consider.

Budget Special edition: What you need to do
31:17

ETFs...What's next? (with Vanguard CEO Daniel Shrimski)
28:59

Beyond property: Why it's time to widen your investment horizon
25:46